The United States Monoclonal Antibodies Industry is Expected to Reach $45.2 Billion by 2027 – – QNT Press Release

The “Monoclonal Antibodies Market Research Report by Source Type (Chimeric, Human, and Humanized), Production Type, Indication, End-User, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to’s offering.

The United States Monoclonal Antibodies Market size was estimated at USD 20.40 billion in 2021, USD 24.06 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 14.21% to reach USD 45.29 billion by 2027.

Companies Mentioned

  • Abbott Laboratories

  • AbbVie, Inc

  • AbGenomics

  • ADC Therapeutics

  • ALMAC Group

  • Amgen Inc.

  • Astellas Pharma Inc

  • AstraZeneca PLC

  • Bayer AG

  • Biogen Idec Inc.

  • Bristol Myers Squibb

  • Daiichi Sankyo Company, Limited

  • Eli Lilly and Company

  • F. Hoffmann-La Roche AG

  • GenScript Biotech Corporation

  • GlaxoSmithKline PLC

  • Johnson & Johnson Services, Inc.

  • Merck & Co., Inc.

  • Mylan NV

  • Novartis International AG

  • Novo Nordisk A/S

  • Pfizer Inc

  • Sanofi SA

  • Seagen Inc.

  • Shanghai Junshi Biosciences Co., Ltd.

  • Thermo Fisher Scientific, Inc

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive mergers and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Monoclonal Antibodies Market based on Business Strategy …

Full story available on

Source link

Recommended For You

About the Author: News Center